Table 1. Clinicopathological features of the 129 patients and the tumor tissue samples.
Variable | No. (%) | The mRNA expression of S100A6 (mean ± SD) | P value |
---|---|---|---|
Gender | P = 0.461 | ||
Male | 90(69.8) | 0.028 ± 0.004 | |
Female | 39(30.2) | 0.033 ± 0.007 | |
Age(year) | P = 0.526 | ||
≤40 | 22(17.1) | 0.026 ± 0.009 | |
>40, ≤60 | 78(60.4) | 0.033 ± 0.005 | |
>60 | 29(22.5) | 0.023 ± 0.006 | |
BMI | P = 0.832 | ||
<25 | 85(65.9) | 0.025 ± 0.013 | |
≥25 | 44(34.1) | 0.031 ± 0.022 | |
Tumor size(cm) | P = 0.0003*** | ||
≤4 | 62(48.1) | 0.021 ± 0.004 | |
>4, ≤7 | 51(39.5) | 0.030 ± 0.006 | |
>7 | 16(12.4) | 0.054 ± 0.017 | |
Fuhrman | P = 0.037* | ||
I | 26(20.2) | 0.021 ± 0.0047 | |
II | 82(63.6) | 0.026 ± 0.0045 | |
III | 19(14.7) | 0.048 ± 0.012 | |
IV | 2(1.5) | 0.109 ± 0.064 | |
TNM Stage | P = 0.0002*** | ||
I | 106(82.1) | 0.237 ± 0.004 | |
II | 5(3.9) | 0.029 ± 0.022 | |
III | 10(7.8) | 0.032 ± 0.015 | |
IV | 8(6.2) | 0.91 ± 0.016 | |
Metastatic status | P = 0.0014** | ||
NM | 111(86.0) | 0.024 ± 0.004 | |
LM | 8(6.2) | 0.082 ± 0.024 | |
DM | 10(7.8) | 0.051 ± 0.016 |
TNM Stage: TNM stage grouping was according to the 2009 TNM staging classification system. Stage I: T1N0M0, Stage II: T2N0M0, Stage III: T3N0(N1)M0, T1(T2)N1M0, Stage IV: T4N0–2M0, T1–4N2M0, T1–4N0–2M1. Abbreviation: BMI: body mass index; NM tumors involving non-metastasis; LM: tumors involving lymphatic metastasis; HM: tumors involving distant organ metastasis. Statistical analysis were described in Materials and Methods.